More News! 5 Aug 2019 Phase II Promise for Inhaled Chronic Lung Disease Treatment A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […] August 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 1 Aug 2019 Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […] August 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 25 Jul 2019 German Biotech Breath Therapeutics Acquired in Deal Worth up to €500M The Italian company Zambon has acquired the German biotech Breath Therapeutics for up to €500M, getting hold of its treatment for a rare lung disease known as popcorn lung. The deal includes an upfront payment of €140M and up to €360M upon reaching undisclosed regulatory milestones. Zambon will take over the development of a treatment […] July 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt will pay Silence Therapeutics €17.8M ($20M) upfront, and up to €600M ($673M) in developmental milestone payments. In exchange, it will get a license for an […] July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 19 Jul 2019 UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […] July 19, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 18 Jul 2019 Swiss Pneumonia Antibiotic Abandoned in Phase III The Swiss biotech Polyphor has discontinued two phase III trials of its antibiotic for treating pneumonia after halting both trials due to safety concerns in May. The two phase III trials were testing Polyphor’s intravenous antibiotic murepavadin in hospitalized patients with pneumonia. In May, Polyphor halted the two trials due to an unexpectedly high incidence […] July 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2019 Scientists in Belgium Cure Anthrax in Mice by Smashing Bacteria’s Armor Belgian researchers have developed a potential treatment for anthrax that breaks down the bacteria’s thick protein armor. Anthrax is a deadly type of bacteria famous for its use in terrorist attacks in 2001. Although anthrax infections can be treated with antibiotics, they can prove hard to treat when the bacteria are inhaled or ingested. Scientists […] July 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2019 Bayer Launches Israeli Company to Develop Viruses Against Crop Disease Bayer is backing the launch of the Israeli biotech Ecophage, which will develop environmentally friendly crop disease treatments based on bacteria-hunting viruses called bacteriophages. Bacteria can cause a range of diseases in crops, including blight and root rot. These infections are often hard to control because they happen faster than fungal infections. The treatments used […] July 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 11 Jul 2019 French Company Raises €29M to Sell Supplements and Cosmetics from Microalgae The French biotech Microphyt has raised €28.5M ($32M) to commercialize nutritional and cosmetic products harvested from microalgae. Over the next 18 months, Microphyt will use the money to ramp up its workforce and industrial capacity in preparation for pushing its microalgal food ingredients and cosmetics to market. The company is developing technology to overcome a […] July 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 4 Jul 2019 First Eco-Friendly Treatment Stops Fungal Crop Disease An eco-friendly antifungal treatment developed by the French biotech Amoéba has reduced rust infections in legumes by 85% in a recent field trial. Rust is a plant disease caused by fungi that is very hard to treat. Although chemical fungicides can be used against it, these are often expensive and harmful to other organisms, including […] July 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […] June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 26 Jun 2019 Carbios Raises €14.5M to Build Plant to Make 100% Recycled Plastic The French bioplastics biotech Carbios has raised €14.5M through a placing of shares in order to fund the construction of a demonstration plant that will use enzymes to make 100% recycled plastics. Around 75% of the proceeds will fund the demonstration plant, which is due to be fully operational by the end of next year. […] June 26, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email